Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

Chee Kay Cheung MBChB PhD, is a consultant nephrologist and honorary senior lecturer at the University of Leicester.

Future Directions in IgAN

In the closing discussion, the panel looks ahead to how IgA nephropathy treatment may continue to evolve. They highlight growing momentum toward earlier, mechanism-based intervention, particularly with B-cell pathway modulators that reduce production of galactose-deficient IgA1 at its origin. The group emphasizes the need for long-term data to understand durability of proteinuria response, immunoglobulin stability, and overall kidney function trajectories with extended use of these therapies. They also discuss the future role of biomarkers—including serum Gd-IgA1 levels, complement activation markers, and genetic signatures—which may eventually help match the right therapy to the right patient rather than relying primarily on proteinuria thresholds. Combination strategies are noted as an emerging research priority, especially pairing supportive care with targeted immunomodulation. The panel closes by expressing optimism that continued collaboration among clinicians, researchers, and patients will meaningfully improve outcomes and reduce progression to kidney failure over time.

Videos

In the closing discussion, the panel looks ahead to how IgA nephropathy treatment may continue to evolve.

Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Courtney Balentine, MD, MPH, is an associate professor in the department of surgery at the University of Wisconsin School of Medicine and Public Health and director of the Wisconsin Surgical Outcomes Research Program.

Bringing AI to the OR: Real-World Challenges And What’s Next, With Courtney Balentine, MD, MPH

As AI continues to gain traction across medicine, the operating room presents a uniquely challenging environment for meaningful implementation of this technology.

 provides novel insight into how emerging AI technology, specifically the OR Black Box, is being adopted in real-world surgical environments and why expectations often outpace reality.

By comparing how different hospitals deployed the tool, how clinicians perceived and interacted with it, and what structural or communication factors influenced success, the study uncovered substantial variability in implementation. It also identified a consistent gap between what surgical teams expected the AI to do and what it was actually able to deliver, driven by both technological limitations and challenges in conveying the system’s purpose and capabilities to frontline surgeons.

“[Large language models] are trained primarily on text data, so you give them reams and reams of books and papers and all sorts of fun stuff from the internet to learn from, and that is definitely not how the OR is structured,” study author Courtney Balentine, MD, MPH, an associate professor in the department of surgery at the University of Wisconsin School of Medicine and Public Health and director of the Wisconsin Surgical Outcomes Research Program, told 

. “It's not served up and ready to go. You have a whole bunch of different streams of information, you have multiple people in different roles who are talking to and across each other, communicating for different purposes at different times, and it's hard to parse all that out.”

According to Balentine, this complexity not only challenges the technology but also affects surgeon engagement. If clinicians cannot clearly see the value, he says adoption suffers.

His qualitative study was conducted at 3 large academic centers via semistructured interviews with surgeons and implementation leaders of the AI intervention to identify areas where expectations of the technology misaligned with their experiences. A total of 30 surgeons and 17 implementation leaders from 3 centers that implemented the AI intervention were interviewed.

Results showed most surgeons (57%) had neutral views of the technology, 37% expressed positive views, and 7% had negative views. Interviewees identified 4 major themes that highlighted misalignment between user expectations and the experience of using the technology:

The artificial intelligence model needed considerable additional training to be usable

Accessing data on surgical cases was difficult and time consuming

The program showed limited ability to predict postoperative complications

The program generated few academic deliverables

Balentine noted that the sites involved in the study varied widely in how they introduced the system, communicated its purpose, selected modules, and aligned the tool with local goals, which in turn impacted how well the technology was received and utilized.

Even at sites where leadership invested heavily in education and transparency, he said misunderstanding frequently persisted, with many frontline surgeons still struggling to grasp what the technology could realistically do versus what they assumed AI should be able to do. This disconnect highlights the need for more effective communication strategies and better expectation-setting around AI capabilities.

“Our take home [message] was that more thought needs to go into how to get the information out and break through that ‘It's AI, so it must do everything’ kind of perspective,” Balentine said.

Looking ahead, he expressed optimism about the potential of OR-based AI to improve outcomes beyond the operating room. Early gains, he said, are most achievable in areas like safety checklists, specimen handling, education, and audit-and-feedback processes.

The larger challenge, and ultimate goal, is linking intraoperative behaviors to downstream patient outcomes. While that requires significant case volume and cross-institutional data, Balentine described it as the next critical step in moving from process improvement to true outcome-driven surgical innovation.

Editors’ Note: Balentine reported grants from the US National Institute on Aging during the conduct of the study.

Thornton M, Cher BAY, Macdonald C, et al. Expectations vs Reality of an Intraoperative Artificial Intelligence Intervention. 

Peregin T. Black Box Technology Shines Light on Improving OR Safety, Efficiency. July 10, 2023. Accessed January 20, 2026. 

https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2023/july-2023-volume-108-issue-7/black-box-technology-shines-light-on-improving-or-safety-efficiency/

Balentine explains the unique challenges of AI implementation in surgery and reviews his research on current barriers to real-world uptake.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Surgery

The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.

Tim Pflederer, MD, is the chief medical officer at Evergreen Nephrology

New Federal Dietary Guidelines Impact on Chronic Kidney Disease Management With Tim Pflederer, MD

The newly released 2025–2030 federal dietary guidelines for Americans may need careful interpretation for patients with 

, particularly regarding encouraged protein intake.

The guidelines, released by the U.S. Department of Health and Human Services (HHS), emphasize protein, recommend limiting processed foods, and encourage a shift toward whole foods. While these recommendations aim to promote general health in the American population, patients with CKD may require tailored guidance based on their kidney function and individual health status.

Ultimately, nephrologists play a key role in bridging the gap between generalized dietary guidelines and the specific needs of patients with CKD. Dietary management in CKD can also help prevent cardiovascular complications and aid in controlling hypertension and diabetes, common comorbidities. In addition, nutrition may influence how well treatments for kidney disease work. The American Kidney Fund recommends working with a dietitian to develop an individualized, kidney-friendly eating plan accounting for disease stage, comorbidities, and dialysis status.

“A diet that is predominantly plant-based is more protective for the kidneys than a meat-based diet,” said Tim Pflederer, MD, chief medical officer at Evergreen Nephrology in an interview with 

Most Americans consume diets heavily centered on meat, so nephrologists work with our patients to encourage moderation in protein intake and a focus on vegetarian or plant-focused protein sources.”

Excess protein intake, particularly from animal sources, increases glomerular filtration workload and generates higher levels of nitrogenous waste, such as urea, which can accumulate in patients with reduced kidney function. High protein diets, especially from meat, can also increase intraglomerular pressure and accelerate kidney damage over time.

Plant-based proteins, such as beans, lentils, and nuts, are easier on the kidneys because they generate less acid, produce lower levels of uremic toxins, and contain phosphorus in a less bioavailable form than animal proteins, reducing the risk of hyperphosphatemia. Diets high in acid-producing foods can exacerbate metabolic acidosis, which is common in CKD and contributes to bone demineralization, progression of kidney damage, and increased muscle catabolism.

“I would divide people with kidney disease into two categories. One is those with CKD who have who whose kidneys are functioning adequately and they're not yet progressed to where they're on dialysis,” said Pflederer. “In that group of patients, it is very clear from the literature that a moderate protein diet is protective of the kidneys compared to a high protein diet, and then actually more importantly is that proteins that are plant based are better for the kidneys.”

Conversely, insufficient protein intake can lead to loss of lean body mass, sarcopenia, and impaired immune function, particularly in patients on dialysis who have higher protein requirements to compensate for amino acid losses during treatment. The optimal protein intake depends on individualized factors including CKD stage, dialysis status, body weight, and comorbid conditions, balancing the need to preserve muscle mass while minimizing renal stress.

Editor’s Note: Pflederer reports no relevant disclosures.

Fact Sheet: Trump Administration Resets U.S. Nutrition Policy, Puts Real Food Back at the Center of Health. HHS.gov. Published January 7, 2026. 

https://www.hhs.gov/press-room/fact-sheet-historic-reset-federal-nutrition-policy.html

American Kidney Fund. Kidney-friendly eating plan | American kidney fund. www.kidneyfund.org. Published December 1, 2021. 

https://www.kidneyfund.org/living-kidney-disease/healthy-eating-activity/kidney-friendly-eating-plan

National Kidney Foundation. Nutrition and Kidney Disease, Stages 1-5 (Not on Dialysis). National Kidney Foundation. Published 2024. 

https://www.kidney.org/kidney-topics/nutrition-and-kidney-disease-stages-1-5-not-dialysis

‌Healthy eating for adults with chronic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. Published May 10, 2025. 

https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/healthy-eating-adults-chronic-kidney-disease

Ko GJ, Kalantar-Zadeh K. How important is dietary management in chronic kidney disease progression? A role for low protein diets. 

Updated federal guidelines highlight protein intake, with Tim Pflederer emphasizing the importance of individualized nutrition strategies for CKD patients


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Andrew Vissing, MD, an attending physician and assistant professor at Northwestern University Feinberg School of Medicine.

 in glomerular disease outcomes among patients aged 14–25 years, clinicians may need to implement more frequent follow-ups to help young adults balance competing priorities.

“Care should always be individualized, but this age group often requires additional nuance. A 20-year-old with glomerular disease can vary widely in independence and ability to manage a complex medical condition,” explained Andrew Vissing, MD, an attending physician and assistant professor at Northwestern University Feinberg School of Medicine, in an interview with 

. “Early in diagnosis, these diseases often require close follow-up, and adolescents and young adults are at higher risk of being lost to follow-up because of competing life priorities.”

Findings from the Cure Glomerulonephropathy (CureGN) consortium in patients with 

focal segmental glomerulosclerosis (FSGS)

 highlight unique disease trajectories in this age group, including higher relapse rates, faster kidney function decline, and, in some cases, quicker remission.

These differences suggest clinicians should not rely on arbitrary age cutoffs but instead view adolescents and young adults as a distinct group requiring tailored monitoring and treatment strategies.

In the United States, an estimated 0.4% of adolescents aged 12–17 have some form of 

, with glomerular diseases accounting for roughly 18% of pediatric kidney disease cases and affecting thousands. Previous CureGN research suggested that approximately 25% of individuals with adolescent-onset glomerular disease reached the composite eGFR decline outcome within five years, reflecting an increased risk of disease progression compared with both younger and older patients.

Globally, glomerular disease affects millions, and incidence has been increasing over the past decades, highlighting the growing need for age-specific care models.

Adolescence and young adulthood are transitional periods, particularly for patients managing glomerular disease. The focus on newfound independence, social pressures, and adjusting to careers can push disease management to the background. Additionally, this period also often coincides with transitions from pediatric to adult care providers, which can disrupt continuity and contribute to missed appointments or delayed treatment adjustments.

From Vissing’s perspective, many patients in this age group may not initially grasp the seriousness of their disease. To address this, he implements shorter follow-up windows and frequently involves nurses or social workers to facilitate laboratory testing, medication access, and appointment adherence.

This approach of increased support and monitoring benefits patients struggling to manage their own care. At the same time, Vissing notes he finds some young adults are capable of independently managing their kidney health, highlighting the need for flexible care strategies tailored to each patient’s level of independence.

Another challenge for this population is limited access to newer therapies and clinical trial participation due to age-based cutoffs, typically set at 18 years. While this was not the focus of the study, Vissing emphasized it as an important area for improving care.

“Pediatric patients < 18 are often excluded from trials of new medications, and it can take years for approved adult therapies to become available to younger patients,” he said. “While this was beyond the scope of our study, it highlights an important gap for adolescents and young adults, particularly those who fall just under age-based eligibility thresholds despite potentially benefiting from these treatments.”

Taken together, these findings underscore the need for clinicians to develop structured follow-up plans, consider multidisciplinary support, and advocate for trial inclusion to optimize outcomes for this age group.

Editor’s Note: Vissing reports no relevant disclosures.

Vissing A, Fishbein J, Smith AR, et al. Is Age Just a Number? Kidney360. Published online December 23, 2025. doi:

Garrity K, Putnam N, Kamil ES, et al. Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database. Pediatric Nephrology. Published online December 27, 2024. doi:

https://doi.org/10.1007/s00467-024-06566-4

Sun P, Ming X, Song T, et al. Global burden of chronic kidney disease in adolescents and young adults, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Frontiers in Endocrinology. 2024;15. doi:

https://doi.org/10.3389/fendo.2024.1389342

World Health Organization. Coming of age: adolescent health. www.who.int. Published 2024. 

https://www.who.int/news-room/spotlight/coming-of-age-adolescent-health

Podcasts

Andrew Vissing shares his clinical perspective and strategies to mitigate gaps in care and management for young adults with glomerular disease.


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Implementing Age-Specific Care For Young Adults With Glomerular Disease With Andrew Vissing, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The American College of Chest Physicians (CHEST) has released a new clinical guideline on biologic management in severe 

, including 7 evidence-based recommendations for pulmonologists, allergists, and immunologists to inform treatment decision making, many of which favor dupilumab for treatment.

“Severe asthma affects 5% to 10% of asthma patients but constitutes close to one-half of the medical costs related to asthma due to higher morbidity and health care utilization. Biologic agents have become a standard of care in those unresponsive to standard treatments, yet the choice of biologic agent is complex due to the varying mechanisms of action, efficacies, and lack of head-to-head comparisons. Therefore, clinicians need further clinical guidance to optimize their use,” lead author on the guideline, Amber J. Oberle, MD, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Duke University, Durham, North Carolina, and colleagues wrote.

Oberle and colleagues conducted a systematic literature review of randomized controlled trials (RCTs) and systematic reviews published in English in the MEDLINE, EMBASE, CINAHL, Web of Science, and CENTRAL databases through August 2024 to address 7 questions developed by an ACCP expert panel of 12 pulmonologists and allergists from 3 countries and created recommendations using The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to assess the certainty of evidence and grading of the clinical recommendations.

“While there are studies available to help guide the clinician for initial biologic selection, to date, there is no published guideline to assist in biologic selection when a patient has tried and failed one or more biologics,” Amber J. Oberle, MD, lead author on the guideline, said in a statement.

 “In addition to following this guideline, decisions as to how to individualize biological therapy should occur under a shared decision-making process that carefully considers underlying asthma comorbidities, T2 biomarkers, injection frequency, mode of administration, and access to resources.”

Should adults with moderate to severe allergic asthma and a history of at least 1 exacerbation annually requiring oral corticosteroids (OCS) use dupilumab or omalizumab?

In adult patients with moderate to severe allergic asthma and a history of ≥ one exacerbation per year requiring oral corticosteroids, the panel conditionally recommends (very low certainty of evidence) either omalizumab or dupilumab; however, for patients with more frequent or severe exacerbations requiring hospitalization, the panel recommends dupilumab over omalizumab.

Should adults with steroid dependent asthma use anti-IL5/5Rα or dupilumab?

For adults with severe, steroid-dependent asthma, the panel conditionally recommends (very low certainty of evidence) anti–IL-5/5Rα therapy or dupilumab, with anti–IL-5/5Rα favored in patients with very high pre-OCS eosinophil counts. Dupilumab should be considered when comorbid atopic dermatitis or eosinophilic esophagitis are present, or either dupilumab or mepolizumab if CRSwNP is present.

Should adults with steroid dependent asthma use dupilumab or tezepelumab?

In OCS-dependent severe asthma, dupilumab is conditionally recommended over tezepelumab due to its demonstrated ability to reduce OCS dosing, despite both agents improving key asthma outcomes and lacking direct comparative trials.

Should adults with moderate to severe asthma not showing clinical response to omalizumab after 4 to 6 months switch to anti-IL5/5Rα therapy or dupilumab?

For adults with moderate to severe asthma who fail to respond to omalizumab after 4–6 months, the guideline suggests switching to anti–IL-5/5Rα therapy or dupilumab, with agent selection guided by biomarkers such as FENO, eosinophil counts, and comorbidities.

Should adults with severe asthma not showing clinical response to anti-IL5/5Rα therapy after 4 to 6 months switch to dupilumab or tezepelumab?

Among patients with severe asthma who do not respond to anti–IL-5/5Rα therapy, the panel conditionally recommends dupilumab or tezepelumab, favoring dupilumab in those who are OCS dependent or have OCS-related complications.

Should adults with severe asthma not showing clinical response to dupilumab after 4 to 6 months switch to anti-IL5/5Rα therapy or tezepelumab?

For adults with severe asthma who fail dupilumab after 4–6 months, anti–IL-5/5Rα therapy or tezepelumab is conditionally recommended, with anti–IL-5/5Rα favored in steroid-dependent patients and tezepelumab considered in those with low eosinophils or low FENO.

Should fractional exhaled nitric oxide (FENO) levels guide therapy changes to dupilumab in adults with severe asthma on anti-IL5/5Rα therapy not showing clinical response by 4 to 6 months?

The guideline suggests using a post-treatment FENO ≥25 ppb to help guide a switch to dupilumab in patients who fail anti–IL-5/5Rα therapy, while emphasizing that FENO should be interpreted alongside clinical factors and alternative options such as tezepelumab.

“Given that there are currently no comparative effectiveness studies, nor is there a validated, commonly agreed definition of clinical response, biologic therapies can only be individualized in daily practice using indirect comparisons of data (delineated into conditional recommendations),” Oberle and colleagues wrote in the guideline.

“Decisions as to how to individualize biologic therapy should occur under a shared decision-making process that carefully considers underlying asthma comorbidities, T2 biomarkers, injection frequency, mode of administration, and access to resources.”

Oberle AJ, Abbas F, Adrish M, et al. Biologic Management in Severe Asthma for Adults: An American College of Chest Physicians Clinical Practice Guideline. CHEST. Published online September 24, 2025. doi: 10.1016/j.chest.2025.08.042

CHEST releases guideline on biologic management in severe asthma. EurekAlert! Published January 13, 2026. Accessed January 20, 2026. https://www.eurekalert.org/news-releases/1112522

Articles

The American College of Chest Physicians has issued a new guideline on biologic management for severe asthma, providing seven evidence-based recommendations. These guidelines aim to assist pulmonologists, allergists, and immunologists in making informed treatment decisions, particularly favoring dupilumab in certain scenarios. The recommendations address various clinical situations, such as steroid-dependent asthma and non-responsiveness to initial biologic treatments. The guideline emphasizes the importance of shared decision-making, considering factors like asthma comorbidities, T2 biomarkers, and treatment accessibility, due to the absence of direct comparative studies and a standardized definition of clinical response.

New guidelines on biologic management for severe asthma provide essential recommendations for optimizing treatment choices among clinicians.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

New CHEST Recommendations Guide Biologic Use for Severe Asthma

This segment of the most recent episode of Skin of Color Savvy highlights a conversation between Shawn Kwatra, MD, and Andrew Alexis, MD, MPH.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Improving Recognition of Skin Disease in Diverse Skin Types, With Shawn Kwatra, MD, and Andrew Alexis, MD, MPH

In a 26-week study, adjunctive seltorexant showed no average weight gain in obese patients with MDD and insomnia unlike quetiapine, according to data presented at ACNP 2026.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Seltorexant Limits Weight Gain in Obesity, MDD, With Celine Goldberger, MD, PhD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This segment of Diabetes Dialogue spotlights the recent announcement of a partnership between Diabeloop and Sequel Med Tech.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabeloop’s DBLG2 and a Closed Loop With the Twiist Delivery System for T1D

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Highlights From the Most-Watched Episodes of 2025

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPen

Sonalika Khachikian, MD, is an endocrinologist at Monument Health.

Rapid advances in immunology are expanding the therapeutic landscape for thyroid eye disease beyond first-in-class IGF-1 receptor inhibition.

Emerging Biologic Targets and Disease Heterogeneity in TED

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

Hepatology

Liver Transplant Access in the MELD 3.0 Era: Progress, Limitations, and Lingering Gaps

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Michael E. Thase, MD, of the University of Pennsylvania

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

Latest News

Future Directions in IgAN

Bringing AI to the OR: Real-World Challenges And What’s Next, With Courtney Balentine, MD, MPH

New Federal Dietary Guidelines Impact on Chronic Kidney Disease Management With Tim Pflederer, MD

Implementing Age-Specific Care For Young Adults With Glomerular Disease With Andrew Vissing, MD

New CHEST Recommendations Guide Biologic Use for Severe Asthma